These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
5. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Kohn EC; Reed E; Sarosy G; Christian M; Link CJ; Cole K; Figg WD; Davis PA; Jacob J; Goldspiel B; Liotta LA Cancer Res; 1996 Feb; 56(3):569-73. PubMed ID: 8564973 [TBL] [Abstract][Full Text] [Related]
6. Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model. Perabo FG; Demant AW; Wirger A; Schmidt DH; Sitia M; Wardelmann E; Müller SC; Kohn EC Anticancer Res; 2005; 25(2A):725-9. PubMed ID: 15868902 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole. Wu Y; Palad AJ; Wasilenko WJ; Blackmore PF; Pincus WA; Schechter GL; Spoonster JR; Kohn EC; Somers KD Clin Cancer Res; 1997 Nov; 3(11):1915-21. PubMed ID: 9815580 [TBL] [Abstract][Full Text] [Related]
8. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. O'Byrne KJ; Steward WP Expert Opin Emerg Drugs; 2001 Apr; 6(1):155-74. PubMed ID: 15989502 [TBL] [Abstract][Full Text] [Related]
9. The role of calcium in the regulation of invasion and angiogenesis. Alessandro R; Masiero L; Liotta LA; Kohn EC In Vivo; 1996; 10(2):153-60. PubMed ID: 8744794 [TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibition in solid tumors. Rosen LS Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425 [TBL] [Abstract][Full Text] [Related]
12. [Inhibition of tumor angiogenesis as a cancer treatment]. Verheul HM; Bom JB; Hoekman K; Pinedo HM Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1549-55. PubMed ID: 10443279 [TBL] [Abstract][Full Text] [Related]
13. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro. Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705 [TBL] [Abstract][Full Text] [Related]
14. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related]
16. Targeting angiogenesis for the treatment of sarcoma. Balasubramanian L; Evens AM Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130 [TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Bauer KS; Figg WD; Hamilton JM; Jones EC; Premkumar A; Steinberg SM; Dyer V; Linehan WM; Pluda JM; Reed E Clin Cancer Res; 1999 Sep; 5(9):2324-9. PubMed ID: 10499600 [TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials. Mross K Drug Resist Updat; 2000 Aug; 3(4):223-235. PubMed ID: 11498390 [TBL] [Abstract][Full Text] [Related]
20. Tumor Growth: A Putative Role for Platelets? Verheul HM; Pinedo HM Oncologist; 1998; 3(2):II. PubMed ID: 10388096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]